| West County Spine & Joint | |
|
355 Ozark Trail Dr, Suite #9, Ellisville, MO 63011-2164 | |
| (636) 394-2225 | |
| Not Available |
| Full Name | West County Spine & Joint |
|---|---|
| Type | Facility |
| Speciality | Chiropractor - Sports Physician |
| Location | 355 Ozark Trail Dr, Ellisville, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487954434 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111NS0005X | Chiropractor - Sports Physician | 2010013424 (Missouri) | Primary |
| Provider Name | Lauren E Hendrix |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1316264237 PECOS PAC ID: 2567656788 Enrollment ID: I20101102000555 |
News Archive
A Penn State researcher argues that ambiguous international rules outlining when and how governments may "break" pharmaceutical patents may end up significantly reducing incentives for innovation while at the same time failing to increase access to medicines.
The mean duration of untreated bipolar disorder is "unacceptably" long, say French researchers who report that an increased duration is associated with more mood episodes, more suicidal behavior, and greater mood instability.
Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of its human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.
Black skin cancer, also known as melanoma, is particularly aggressive and becoming increasingly common in Switzerland. Despite intensive research, however, there is still no treatment. Researchers from the University of Zurich have now discovered a gene that plays a central role in black skin cancer. Suppressing this gene in mice inhibits the development of melanoma and its proliferation - a discovery that could pave the way for new forms of therapy.
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
› Verified 8 days ago
| Provider Name | Matthew L Davidson |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1255624508 PECOS PAC ID: 4587825203 Enrollment ID: I20120405000367 |
News Archive
A Penn State researcher argues that ambiguous international rules outlining when and how governments may "break" pharmaceutical patents may end up significantly reducing incentives for innovation while at the same time failing to increase access to medicines.
The mean duration of untreated bipolar disorder is "unacceptably" long, say French researchers who report that an increased duration is associated with more mood episodes, more suicidal behavior, and greater mood instability.
Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of its human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.
Black skin cancer, also known as melanoma, is particularly aggressive and becoming increasingly common in Switzerland. Despite intensive research, however, there is still no treatment. Researchers from the University of Zurich have now discovered a gene that plays a central role in black skin cancer. Suppressing this gene in mice inhibits the development of melanoma and its proliferation - a discovery that could pave the way for new forms of therapy.
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
› Verified 8 days ago
| Provider Name | Alexandra M Johler |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1508496480 PECOS PAC ID: 4981032505 Enrollment ID: I20200313001921 |
News Archive
A Penn State researcher argues that ambiguous international rules outlining when and how governments may "break" pharmaceutical patents may end up significantly reducing incentives for innovation while at the same time failing to increase access to medicines.
The mean duration of untreated bipolar disorder is "unacceptably" long, say French researchers who report that an increased duration is associated with more mood episodes, more suicidal behavior, and greater mood instability.
Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of its human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.
Black skin cancer, also known as melanoma, is particularly aggressive and becoming increasingly common in Switzerland. Despite intensive research, however, there is still no treatment. Researchers from the University of Zurich have now discovered a gene that plays a central role in black skin cancer. Suppressing this gene in mice inhibits the development of melanoma and its proliferation - a discovery that could pave the way for new forms of therapy.
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| West County Spine & Joint 355 Ozark Trail Dr, Suite #9, Ellisville, MO 63011-2164 Ph: (636) 394-2225 | West County Spine & Joint 355 Ozark Trail Dr, Suite #9, Ellisville, MO 63011-2164 Ph: (636) 394-2225 |
News Archive
A Penn State researcher argues that ambiguous international rules outlining when and how governments may "break" pharmaceutical patents may end up significantly reducing incentives for innovation while at the same time failing to increase access to medicines.
The mean duration of untreated bipolar disorder is "unacceptably" long, say French researchers who report that an increased duration is associated with more mood episodes, more suicidal behavior, and greater mood instability.
Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of its human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.
Black skin cancer, also known as melanoma, is particularly aggressive and becoming increasingly common in Switzerland. Despite intensive research, however, there is still no treatment. Researchers from the University of Zurich have now discovered a gene that plays a central role in black skin cancer. Suppressing this gene in mice inhibits the development of melanoma and its proliferation - a discovery that could pave the way for new forms of therapy.
Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals.
› Verified 8 days ago
Copeland Chiropractic Pc Chiropractor Medicare: Medicare Enrolled Practice Location: 113 Old State Rd Ste 202, Ellisville, MO 63021 Phone: 636-386-6200 Fax: 636-386-8849 | |
Experience Your Greatness Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 249 Clarkson Rd, Suite 101, Ellisville, MO 63011 Phone: 636-256-0707 | |
Family Wellness Chiropractic, Lcc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 355 Ozark Trail Dr Ste 9, Clayton-clarkson Center, Ellisville, MO 63011 Phone: 636-527-5071 | |
Sahin Dzananovic, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 15876 Fountain Plaza Dr, Ellisville, MO 63011 Phone: 636-251-5556 | |
Aequa Health And Wellness Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 179 Clarkson Executive Park, Ellisville, MO 63011 Phone: 636-227-4442 | |
Dr. David Brian Schaller, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 15825 Manchester Rd, Suite 201, Ellisville, MO 63011 Phone: 636-256-4900 | |
Dr. Delia L Overschmidt, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 355 Ozark Trail Dr Ste 9, Ellisville, MO 63011 Phone: 636-394-2225 |